MTOR and nonpapillary renal cell carcinoma: Current therapeutic interventions against ccRCC include treatment with tyrosine kinase inhibitors (e.g., sunitinib or cabozantinib), combined immunotherapy (e.g., nivolumab and ipilimumab) and targeted therapies (such as the anti-VEGF antibody, bevacizumab, or the mTOR inhibitor, everolimus) [1,34].